Randomization to Extend Stroke Intravenous ThromboLysis In Evolving Non-Large Vessel Occlusion With TNK (RESILIENT

PHASE3RecruitingINTERVENTIONAL
Enrollment

466

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2027

Conditions
Ischemic Stroke, Acute
Interventions
DRUG

Intravenous tenecteplase

Intravenous tenecteplase (TNK). Patients will receive intravenous TNK (0.25mg/kg, maximum 25mg, administered as a bolus over 5 seconds).

DRUG

Placebo

Placebo matching IV TNK

Trial Locations (15)

90035000

RECRUITING

Hospital Moinhos de Vento, Porto Alegre

Unknown

RECRUITING

Hospital das Clínicas Botucatu, Botucatu

RECRUITING

Hospital das Clínicas - UNICAMP, Campinas

RECRUITING

Hospital Universitário Maria Aparecida Pedrossian, Campo Grande

RECRUITING

Hospital das Clínicas UFPR, Curitiba

RECRUITING

Clinica Neurologica e Neurocirurgica de Joinville, Joinville

RECRUITING

Hospital Metropolitano de Maceió, Maceió

RECRUITING

Hospital de Clínicas de Porto Alegre, Porto Alegre

RECRUITING

Hospital de Base São José do Rio Preto, São José do Rio Preto

RECRUITING

Santa Casa de Misericordia de Sao Paulo, São Paulo

RECRUITING

Hospital Estadual Central, Vitória

60175-295

RECRUITING

Hospital Geral de Fortaleza, Fortaleza

90035-007

RECRUITING

Hospital de Clínicas de Porto Alegre, Porto Alegre

14015-010

RECRUITING

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo, Ribeirão Preto

04037-002

RECRUITING

Hospital São Paulo, São Paulo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ministry of Health, Brazil

OTHER_GOV

collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Brainomix Limited

INDUSTRY

collaborator

iSchemaView, Inc

UNKNOWN

lead

Hospital Moinhos de Vento

OTHER

NCT05199662 - Randomization to Extend Stroke Intravenous ThromboLysis In Evolving Non-Large Vessel Occlusion With TNK (RESILIENT | Biotech Hunter | Biotech Hunter